InMode Ltd. (NASDAQ:INMD) Shares Sold by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC trimmed its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 9.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,672 shares of the healthcare company’s stock after selling 578 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in InMode were worth $95,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Systematic Financial Management LP lifted its position in shares of InMode by 13.3% during the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after purchasing an additional 115,492 shares in the last quarter. Barclays PLC increased its stake in shares of InMode by 113.5% in the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock worth $2,876,000 after buying an additional 90,173 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in InMode by 54.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock valued at $2,127,000 after purchasing an additional 44,058 shares during the last quarter. State Street Corp boosted its holdings in shares of InMode by 3.7% during the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock valued at $34,657,000 after acquiring an additional 73,183 shares during the period. Finally, Atlas Legacy Advisors LLC acquired a new position in shares of InMode during the fourth quarter valued at $848,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Performance

Shares of NASDAQ INMD opened at $18.35 on Tuesday. The business has a fifty day moving average of $17.95 and a two-hundred day moving average of $17.64. InMode Ltd. has a 52-week low of $14.87 and a 52-week high of $21.92. The stock has a market cap of $1.28 billion, a PE ratio of 7.81 and a beta of 2.08.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Barclays increased their price target on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $22.25.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.